Shah Jatin 4
4 · Karyopharm Therapeutics Inc. · Filed May 11, 2021
Insider Transaction Report
Form 4
Shah Jatin
EVP, Chief Medical Officer
Transactions
- Purchase
Common Stock
2021-05-07$8.60/sh+23,250$199,992→ 131,802 total
Footnotes (2)
- [F1]Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $8.5850 to $8.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F2]Includes 861 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2021.